Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Vaccinia × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 109 Carcinoma, Renal Cell 52 Liver Neoplasms 39 Neoplasms 38 Neoplasm Metastasis 18 Leukemia, Myeloid, Acute 18 Carcinoma, Non-Small-Cell Lung 18 Melanoma 17 Breast Neoplasms 16 Kidney Neoplasms 15 Sarcoma 11 Pancreatic Neoplasms 11 Brain Neoplasms 11 Prostatic Neoplasms 9 Recurrence 8 Lung Neoplasms 8 Glioblastoma 8 Colorectal Neoplasms 8 Thyroid Neoplasms 6 Rectal Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Multiple Myeloma 6 Leukemia 6 Unspecified Adult Solid Tumor, Protocol Specific 5 Stomach Neoplasms 5 Colonic Neoplasms 5 Ovarian Neoplasms 4 Osteosarcoma 4 Myelodysplastic Syndromes 4 Lymphoma, Large B-Cell, Diffuse 4

Interventions

pembrolizumab 1 Sorafenib 1 Irinotecan 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Drug Therapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02562755 2020-12-16

PHOCUS

SillaJen, Inc.

Phase 3 Completed

459 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡